Puma Biotechnology, Inc.
NMS: PBYILive Quote
📈 ZcoreAI Score
Our AI model analyzes Puma Biotechnology, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PBYI Z-Score →About Puma Biotechnology, Inc.
Healthcare
Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
📊 Fundamental Analysis
Puma Biotechnology, Inc. demonstrates a healthy profit margin of 13.6%.
The company recently reported 27.7% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 28.0%, which exceeds the Healthcare sector average, reflecting efficient capital allocation.
At a current price of $7.78, PBYI currently trades near the top of its 52-week range (98%) (Range: $2.75 - $7.90).
💰 Valuation Insight
PBYI trades at a 49.0% discount (PE: 12.75), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
✅
Return on Equity
Excellent
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$395.82M
Trailing P/E
12.75
Forward P/E
11.97
Beta (5Y)
1.18
52W High
$7.90
52W Low
$2.75
Avg Volume
408K
Day High
Day Low